Unigene Laboratories, Inc. (UGNE) Cash Flow Statement

Net loss	1.98M
Amortization of deferred revenue	-447.02K
Amortization of debt discounts and deferred financing fees	1.93M
Non-cash equity compensation	266.39K
Depreciation and amortization of long-lived assets	157.36K
Inventory reserve provision	1.64M
Debt issuance cost
Loss on change in fair value of embedded convertible feature
Loss on investment in China joint venture
Loss on investment in Tarsa	0
Decrease in accounts receivable	-19.81K
Decrease in inventory	-374.02K
Increase in other assets	97.13K
(Decrease) increase in accounts payable and accrued expenses	-379.99K
Increase in accrued interest-stockholders	2.58M
Increase (decrease) in deferred compensation	12.13K
Increase in deferred licensing fees	50K
Net cash used in operating activities	-3.41M
Investment in Tarsa	0
Construction of leasehold and building improvements
Purchase of equipment and furniture	0
Increase in patents and other intangibles	-44.78K
Proceeds from sale/lease back
Net cash used in investing activities	-44.78K
Issuance of note payable – Victory Park
Debt issuance cost
Repayment on note payable – China joint venture
Repayment on note payable – Victory Park
Repayment on note payable – Jay Levy
Proceeds from exercise of stock options	0
Net cash provided by financing activities	-9.28K
Net (decrease) increase in cash and cash equivalents	-3.46M
Cash and cash equivalents at beginning of period	3.81M
Cash and cash equivalents at end of period	353.22K
Issuance of convertible note in exchange for nonconvertible note
Cash paid for interest

Entities mentioned with UGNE

View All Entities